EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis

Shuo Yang iD, Shuangqing Xin, Ronghui Ju, Peizhuo Zang

PLOS ONE · 27.02.2025 · 20 (2) · e0314787

DOI: 10.1371/journal.pone.0314787 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 27.02.2025. Verfasst von Shuo Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, …. Hauptthemen laut MEDLINE: Pediatric Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity significantly impacts the health outcomes of children and adolescents, necessitating a comprehensive study to evaluate the effects of various anti-obesity medications (AOMs) on weight-related and metabolic outcomes.

Methods

PubMed, EMBASE, and CENTRAL were searched for studies published up to January 3, 2024. We performed a network meta-analysis on randomized clinical trials that compared various treatments for pediatric and adolescent obesity, such as phentermine/topiramate, semaglutide, exenatide, liraglutide, topiramate, metformin, fluoxetine, metformin/fluoxetine, sibutramine, and orlistat. The study evaluated body mass index (BMI), BMI percentage change, weight, BMI-SDS, waist circumference, metabolic, anthropometric, and safety outcomes.

Results

The study gathered 2733 studies, including 30 articles that involved 3822 participants. The results of our research showed that PHEN/TPM was better at lowering BMI than exenatide, liraglutide, metformin, fluoxetine, Met/Flu, topiramate, orlistat, and sibutramine, with mean differences (MD) ranging from −10.29 to −1.28. Additionally, semaglutide demonstrated superior efficacy over other AOMs (MD ranged from −8.28 to −1.24). Various levels of certainty, ranging from very low to moderate, supported the findings. Furthermore, semaglutide demonstrated superior efficacy over exenatide (MD-12.43, 95% CI −23.95 to −0.30) regarding percentage change in BMI. Semaglutide also showed enhanced weight reduction effectiveness compared to seven other AOMs except for PHEN/TPM (MD ranging from −15.56 to −12.65). Similarly, PHEN/TPM displayed greater weight reduction effectiveness than seven other AOMs, except for semaglutide (MD ranged from −12.17 to −9.27). Moreover, semaglutide proved more effective in decreasing waist circumference when compared with other AOMs apart from PHEN/TPM (MD ranged from −11.61 to −6.07). Similarly, we found that PHEN/TPM, excluding semaglutide and sibutramine, was more effective in reducing waist circumference (MD ranged from −8.64 to −5.51).

Conclusions

The study found that semaglutide outperformed other AOMs in reducing BMI and additional weight-related outcomes in children and adolescents with obesity, while PHEN/TPM showed comparable efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pediatric ObesityAnti-Obesity AgentsHumansAdolescentChildBody Mass IndexRandomized Controlled Trials as Topic

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, China.
  • Department of Radiology, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, China.
  • Department of Cerebrovascular Disease Treatment Center, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, China.

ORCID-Profile: Shuo Yang

Zitieren

APA

Yang, S., Xin, S., Ju, R., & Zang, P. (2025). Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis. PLOS ONE, 20(2), e0314787. https://doi.org/10.1371/journal.pone.0314787

Vancouver

Yang S, Xin S, Ju R, Zang P. Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis. PLOS ONE. 2025;20(2):e0314787. doi:10.1371/journal.pone.0314787

BibTeX
@article{Yang2025,
  author = {Yang, Shuo and Xin, Shuangqing and Ju, Ronghui and Zang, Peizhuo},
  title = {Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {e0314787},
  doi = {10.1371/journal.pone.0314787}
}
Kostenlos starten →